Table 3.
Associations of physical activity pattern and CV and biomarkers of endothelial dysfunction score and low-grade inflammation score
| Physical activity pattern | Biomarkers of endothelial dysfunction | Low-grade inflammation | ||||
|---|---|---|---|---|---|---|
| Model 1 β (95% CI) |
Model 2 β (95% CI) |
Model 3 β (95% CI) |
Model 1 β (95% CI) |
Model 2 β (95% CI) |
Model 3 β (95% CI) |
|
| Insufficiently active | Ref | Ref | Ref | Ref | Ref | Ref |
| Weekend warrior | −0.45 (−0.61, −0.28)*** | −0.41 (−0.58, −0.24)*** | −0.28 (−0.44, −0.11)** | −0.48 (−0.64, −0.31)*** | −0.39 (−0.56, −0.23)*** | −0.22 (−0.38, −0.07)** |
| Regularly active | −0.51 (−0.66, −0.35)*** | −0.47 (−0.63, −0.31)*** | −0.32 (−0.47, −0.16)*** | −0.54 (−0.69, −0.39)*** | −0.46 (−0.61, −0.31)*** | −0.26 (−0.41, −0.11)*** |
| CV | 0.08 (0.05, 0.11)*** | 0.07 (0.04, 0.10)*** | 0.04 (0.01, 0.07)* | 0.11 (0.08, 0.14)*** | 0.09 (0.06, 0.12)*** | 0.05 (0.02, 0.08)** |
Regression results are presented as unstandardised coefficients (β), with 95% CIs
Model 1 was adjusted for age, sex and glucose metabolism status; model 2 was additionally adjusted for smoking, Dutch healthy diet index and level of education; model 3 was additionally adjusted for history of CVD, BMI, office systolic BP, mobility limitation (yes/no), triacylglycerol, total cholesterol/HDL-cholesterol ratio, use of lipid-modifying medication and use of antihypertensive medication
*p<0.05, **p<0.01, ***p<0.001